Perjeta (Pertuzumab)

€3,036.09

Perjeta (pertuzumab) is a medication used for the treatment of HER2 positive breast cancer in patients with metastatic cancer or as neoadjuvant treatment for patients with locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer.

DISEASE INDICATIONS

Breast Cancer

MANUFACTURER

Roche Registration Limited

USAGE

Intravenous

MEDICINE APPROVED BY

European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Therapeutic Goods Administration (TGA)
Medsafe (NZ)

PATIENTS HELPED
- Over 1.2 million patients reached
- More than 11,000 patients helped
- 100% successful deliveries to 88 countries
WE CAN HELP WITH YOUR IMPORT DOCUMENTS

We are experts in import regulations.

PERJETA (PERTUZUMAB) Package

Clear

SKU: N/A Category: Buy Oncology Medicines & Drugs Online

Perjeta (Pertuzumab) for sale – Buy Perjeta (Pertuzumab) Online

What is Perjeta (pertuzumab) for?

Perjeta (pertuzumab) is indicated for the treatment of HER2 positive breast cancer in patients with metastatic cancer or as neoadjuvant treatment for patients with locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer^[1,2,3].

How does Perjeta (pertuzumab) work?

Perjeta (pertuzumab) is used in combination with trastuzumab and docetaxel (other cancer medicines) for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease^[1,2,3].

It is also used in combination with trastuzumab and chemotherapy as neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen for early breast cancer^[1,2,3].

Is Perjeta (pertuzumab) approved?

Perjeta (pertuzumab) was approved for HER2 positive breast cancer in metastatic patients or as neoadjuvant therapy by:

FDA (USA) on June 12, 2012^[5]
EMA (EU) on March 4, 2013^[2]
TGA (AUS) on May 6, 2013^[3]
Health Canada on May 8, 2013^[7]
Medsafe (New Zealand) on July 18, 2013^[8]

How do I take Perjeta (pertuzumab)?

The standard dosage is:

Initial dose: 840 mg administered as a 60-minute intravenous infusion
Following infusions: 420 mg administered as a 30 to 60-minute intravenous infusion every 3 weeks.

Patients with metastatic breast cancer should be treated with pertuzumab and trastuzumab until disease progression or unmanageable toxicity.

Patients in neoadjuvant treatment of breast cancer should be administered pertuzumab every 3 weeks for 3 to 6 cycles before surgery.

Complete information about Perjeta (pertuzumab) dosage and administration can be found in the references section^[2,3,5].

Note: Consult your treating doctor for personalised dosing.